2026 Q2 - tulosraportti
48 päivää sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 95 | - | - | ||
| 1 470 | - | - | ||
| 7 284 | - | - | ||
| 271 | - | - | ||
| 205 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·5 t sittenKDIGO is very aware that diabetics are predisposed to kidney problems and talks a lot about it, but they lack evidence for how to use the NGAL test practically in treatment facilities, It is just a matter of time, and then recommendations for diabetics will also come, because research is being driven at high speed right now. Links are just to show that research is being done into how the NGAL test can be used to detect that the kidneys are stressed in diabetics at an early stage. https://www.researchgate.net/publication/400000494_CLINICAL_UTILITY_OF_NEUTROPHIL_GELATINASE-ASSOCIATED_LIPOCALIN_AS_AN_EARLY_BIOMARKER_OF_DIABETIC_KIDNEY_DISEASE_A_SYSTEMATIC_REVIEW_AND_META-ANALYSIS From KDIGO on Linkedin https://www.linkedin.com/feed/update/urn:li:activity:7510697400466903040/
·7 t sittenBioporto is holding an investor meeting today from 15.00-17.30...maybe there will be good news or investors who quite simply just become even more positive towards the stock when they meet management
Growth It doesn't sound like you have a single reservation about the market that first needs to be created before it can be penetrated.- ·21 t sittenBioporto has shared this on Linkedin, because it is the NGAL test that they have used to arrive at the fact that research shows that NGAL measured in urine is the best biomarker for predicting the risk of death or severe neurological damage after a cardiac arrest. The study concludes that specific renal biomarkers such as NGAL outperform the traditional creatinine standard for early detection of acute kidney injury. The above is published in an article in Resuscitation Journal https://www.resuscitationjournal.com/article/S0300-9572(26)00210-8/abstractIt is a good time that this research has been published, when later this month there is a major kidney trade fair " ASN Kidney Week" where there are representatives from KDIGO's working group present, and who can answer questions about this research, in case there should be any.
- ·1 päivä sitten · MuokattuThe three experts that BioPorto has invited to the trade fair are individuals who have actively participated in KDIGO's working groups regarding the new global recommendations for the NGAL test. These three gentlemen have naturally only said yes to participating because this is a great opportunity for them to get the message out to the various treatment centers about their recommendations for the NGAL test to the entire world. In this way, they do not need to use resources to travel around the world, but the world comes to them. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
- ·2.10. · MuokattuCB has stated that KDIGO will likely finish clean-writing the documents regarding NGAL in Q4. KDIGO has not announced anything regarding a deadline. However, KDIGO has a tradition of using major congresses, including ASN Kidney Week, to spread major news, such as the new recommendations for the NGAL test. If one looks at what is going to happen at "ASN Kidney Week" from October 21 to 25, 2026, courses will be held on the latest updates, including KDIGO's recommendations. There is a probability that CB will be proven right. Ex. Kidney Week 2026: Early programs https://www.asn-online.org/education/kidneyweek/2026/program-early.aspx
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 75 610 | 75 610 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 75 610 | 75 610 | 0 | 0 |
2026 Q2 - tulosraportti
48 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenKDIGO is very aware that diabetics are predisposed to kidney problems and talks a lot about it, but they lack evidence for how to use the NGAL test practically in treatment facilities, It is just a matter of time, and then recommendations for diabetics will also come, because research is being driven at high speed right now. Links are just to show that research is being done into how the NGAL test can be used to detect that the kidneys are stressed in diabetics at an early stage. https://www.researchgate.net/publication/400000494_CLINICAL_UTILITY_OF_NEUTROPHIL_GELATINASE-ASSOCIATED_LIPOCALIN_AS_AN_EARLY_BIOMARKER_OF_DIABETIC_KIDNEY_DISEASE_A_SYSTEMATIC_REVIEW_AND_META-ANALYSIS From KDIGO on Linkedin https://www.linkedin.com/feed/update/urn:li:activity:7510697400466903040/
- ·7 t sittenBioporto is holding an investor meeting today from 15.00-17.30...maybe there will be good news or investors who quite simply just become even more positive towards the stock when they meet managementGrowth It doesn't sound like you have a single reservation about the market that first needs to be created before it can be penetrated.
- ·21 t sittenBioporto has shared this on Linkedin, because it is the NGAL test that they have used to arrive at the fact that research shows that NGAL measured in urine is the best biomarker for predicting the risk of death or severe neurological damage after a cardiac arrest. The study concludes that specific renal biomarkers such as NGAL outperform the traditional creatinine standard for early detection of acute kidney injury. The above is published in an article in Resuscitation Journal https://www.resuscitationjournal.com/article/S0300-9572(26)00210-8/abstractIt is a good time that this research has been published, when later this month there is a major kidney trade fair " ASN Kidney Week" where there are representatives from KDIGO's working group present, and who can answer questions about this research, in case there should be any.
- ·1 päivä sitten · MuokattuThe three experts that BioPorto has invited to the trade fair are individuals who have actively participated in KDIGO's working groups regarding the new global recommendations for the NGAL test. These three gentlemen have naturally only said yes to participating because this is a great opportunity for them to get the message out to the various treatment centers about their recommendations for the NGAL test to the entire world. In this way, they do not need to use resources to travel around the world, but the world comes to them. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
- ·2.10. · MuokattuCB has stated that KDIGO will likely finish clean-writing the documents regarding NGAL in Q4. KDIGO has not announced anything regarding a deadline. However, KDIGO has a tradition of using major congresses, including ASN Kidney Week, to spread major news, such as the new recommendations for the NGAL test. If one looks at what is going to happen at "ASN Kidney Week" from October 21 to 25, 2026, courses will be held on the latest updates, including KDIGO's recommendations. There is a probability that CB will be proven right. Ex. Kidney Week 2026: Early programs https://www.asn-online.org/education/kidneyweek/2026/program-early.aspx
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 95 | - | - | ||
| 1 470 | - | - | ||
| 7 284 | - | - | ||
| 271 | - | - | ||
| 205 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 75 610 | 75 610 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 75 610 | 75 610 | 0 | 0 |
2026 Q2 - tulosraportti
48 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittenKDIGO is very aware that diabetics are predisposed to kidney problems and talks a lot about it, but they lack evidence for how to use the NGAL test practically in treatment facilities, It is just a matter of time, and then recommendations for diabetics will also come, because research is being driven at high speed right now. Links are just to show that research is being done into how the NGAL test can be used to detect that the kidneys are stressed in diabetics at an early stage. https://www.researchgate.net/publication/400000494_CLINICAL_UTILITY_OF_NEUTROPHIL_GELATINASE-ASSOCIATED_LIPOCALIN_AS_AN_EARLY_BIOMARKER_OF_DIABETIC_KIDNEY_DISEASE_A_SYSTEMATIC_REVIEW_AND_META-ANALYSIS From KDIGO on Linkedin https://www.linkedin.com/feed/update/urn:li:activity:7510697400466903040/
- ·7 t sittenBioporto is holding an investor meeting today from 15.00-17.30...maybe there will be good news or investors who quite simply just become even more positive towards the stock when they meet managementGrowth It doesn't sound like you have a single reservation about the market that first needs to be created before it can be penetrated.
- ·21 t sittenBioporto has shared this on Linkedin, because it is the NGAL test that they have used to arrive at the fact that research shows that NGAL measured in urine is the best biomarker for predicting the risk of death or severe neurological damage after a cardiac arrest. The study concludes that specific renal biomarkers such as NGAL outperform the traditional creatinine standard for early detection of acute kidney injury. The above is published in an article in Resuscitation Journal https://www.resuscitationjournal.com/article/S0300-9572(26)00210-8/abstractIt is a good time that this research has been published, when later this month there is a major kidney trade fair " ASN Kidney Week" where there are representatives from KDIGO's working group present, and who can answer questions about this research, in case there should be any.
- ·1 päivä sitten · MuokattuThe three experts that BioPorto has invited to the trade fair are individuals who have actively participated in KDIGO's working groups regarding the new global recommendations for the NGAL test. These three gentlemen have naturally only said yes to participating because this is a great opportunity for them to get the message out to the various treatment centers about their recommendations for the NGAL test to the entire world. In this way, they do not need to use resources to travel around the world, but the world comes to them. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
- ·2.10. · MuokattuCB has stated that KDIGO will likely finish clean-writing the documents regarding NGAL in Q4. KDIGO has not announced anything regarding a deadline. However, KDIGO has a tradition of using major congresses, including ASN Kidney Week, to spread major news, such as the new recommendations for the NGAL test. If one looks at what is going to happen at "ASN Kidney Week" from October 21 to 25, 2026, courses will be held on the latest updates, including KDIGO's recommendations. There is a probability that CB will be proven right. Ex. Kidney Week 2026: Early programs https://www.asn-online.org/education/kidneyweek/2026/program-early.aspx
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 95 | - | - | ||
| 1 470 | - | - | ||
| 7 284 | - | - | ||
| 271 | - | - | ||
| 205 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 75 610 | 75 610 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 75 610 | 75 610 | 0 | 0 |